Comparative Pharmacology
Head-to-head clinical analysis: HEDULIN versus HEPARIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEDULIN versus HEPARIN SODIUM.
HEDULIN vs HEPARIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
Heparin sodium potentiates the activity of antithrombin III, thereby inactivating thrombin and factor Xa, leading to inhibition of coagulation.
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
Intravenous: Initial bolus of 80 units/kg, then continuous infusion at 18 units/kg/h. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
The terminal elimination half-life of heparin is dose-dependent: approximately 30 minutes (low dose, e.g., 25 U/kg), 60 minutes (medium dose, 100 U/kg), and 150 minutes (high dose, 400 U/kg). Half-life increases with dose due to saturation of clearance mechanisms.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Heparin is cleared primarily via the reticuloendothelial system and liver, with minimal renal excretion. Unchanged heparin is not significantly excreted in urine. Biliary/fecal elimination is negligible.
Category C
Category A/B
Anticoagulant
Anticoagulant